PT-141 Pen 10 mg
10mg99,00 € incl. VAT
PT-141 Pen 10 mg: pre-filled pen with PT-141 (bremelanotide, melanocortin receptor agonist) as a ready-to-use solution, 10 mg in a 2 mL cartridge (5 mg/mL). No reconstitution: the dial sets a fixed volume per click. The substance is independently tested by HPLC and the Certificate of Analysis is published on this page. For laboratory research use only.
Pre-order
Shipping from 11,93 € · Free EU shipping over 200 €
📋 View the Certificate of Analysis information
Product specifications
| Quantity | 10mg |
|---|---|
| Unit | 1 pre-filled pen |
| Purity data | >99.8% (batch XD-P41-PO07) |
| Format | Pre-mixed pen (solution in cartridge) |
| Volume | 2 mL solution |
| Concentration | 5 mg/mL |
| Storage | 2–8 °C, protected from light |
| Source lot | XD-P41-PO07, tested by Liquilabs |
Description
Research use only. Sold for laboratory research. Not a medicine, and not for human or veterinary use.
Pre-order
This pen is being prepared for its first production run. Orders placed now are reserved and ship as soon as stock arrives; you will get an email with tracking the day it leaves.
What is PT-141?
PT-141, or bremelanotide, is a cyclic peptide of seven amino acids that activates melanocortin receptors, mainly MC4R and MC3R, in the central nervous system. It was developed from Melanotan II after researchers noticed its effect on sexual arousal. Unlike compounds that act on blood flow, it works through brain pathways involved in desire.
What the research shows
- Sexual desire in women. In the two phase 3 RECONNECT trials (about 1,200 premenopausal women with low sexual desire, 24 weeks), bremelanotide increased desire scores and reduced the related distress compared with placebo. It was approved in the United States on this evidence in 2019.
- Erectile function in men. Earlier phase 2 studies reported an improved erectile response, including in men who had not responded to PDE5 inhibitors.
- Onset. Effects appear within about 45 minutes, and the half-life is roughly 2.7 hours.
Side effects reported in studies
Nausea (about 40% of participants, usually with the first doses), flushing, headache and injection-site reactions. A small, temporary rise in blood pressure occurs after dosing. Darkening of the skin or gums was reported with frequent use.
Doses reported in published studies
The phase 3 trials and the approved labelling use 1.75 mg by subcutaneous injection, taken as needed at least 45 minutes beforehand, with no more than one dose in 24 hours and no more than eight doses a month.
This section summarises the doses used in the published literature. It is not a recommendation.
About the pre-mixed pen format
A pre-mixed pen holds the peptide already reconstituted inside a sealed cartridge, so there is no vial to open, no solvent to measure and no transfer step. The solution stays in a closed system from filling to use, and the dial delivers the same volume on every click. Each pen is filled from a lot of lyophilised substance that has already been through independent testing; the lot number is shown on this page.
Supplied as one pre-filled pen, without other accessories.
Pen or vial?
| Pen | Vial | |
|---|---|---|
| Form on arrival | Solution in a cartridge (dual-chamber: powder and solvent, mixed on activation) | Lyophilised powder |
| Reconstitution | Not needed | Done by the user with bacteriostatic water |
| Measuring | Dial, fixed volume per click | Syringe, calculated per draw |
| Handling steps | One | Several |
| Price per mg | Higher | Lower |
| Best for | Convenience and repeatable volumes | Lowest cost and the longest unopened shelf life |
Prefer the lyophilised vial? See PT-141 10mg.
Storage
Keep the pen refrigerated at 2–8 °C, in its box and away from light. Do not freeze. Do not use if the solution is cloudy, discoloured or contains particles. Short temperature excursions during shipping are expected and are covered by insulated packaging.
Quality and Certificate of Analysis
The substance in this pen comes from lot XD-P41-PO07, tested by Liquilabs, an independent laboratory: >99.8% purity by HPLC, with identity confirmed and endotoxin tested on the same report. The report is published in our lab reports archive, and the lot number can be checked on the laboratory's own site. The certificate describes the lyophilised source lot; the finished solution in the pen has not been analysed separately.
Frequently asked questions
When will my pre-ordered PT-141 Pen 10 mg ship?
As soon as the first production run arrives. You receive tracking by email on the day it leaves.
Does the PT-141 Pen 10 mg need to stay cold?
Yes. Keep it at 2–8 °C. It ships in insulated packaging.
What does the Certificate of Analysis cover?
The lot of lyophilised substance the pen was filled from. The finished solution in the pen has not been analysed separately.
What is in the box?
One pre-filled pen. Needles and other accessories are not included at the moment.
Is it the same substance as the vial?
Yes. It is the same substance in a different format.
Batch test records
The substance in this pen comes from the lot below. The report describes the lyophilised source lot; the finished solution in the pen has not been analysed separately.
- Tested
- September 8, 2026
- Assay
- Purity, Endotoxin
- Purity
- >99.8%
You Might Also Like
BPC-157 Pen 5 mg: pre-filled pen with BPC-157 (synthetic 15-amino-acid peptide) as a ready-to-use solution, 5 mg in a 2 mL cartridge (2.5 mg/mL). No reconstitution: the dial sets a fixed volume per click. The substance is independently tested by HPLC and the Certificate of Analysis is published on this page. For laboratory research use only.
- Purity tested
- Endotoxin tested
- Heavy metals tested
GHK-Cu Pen 50 mg: pre-filled pen with GHK-Cu (copper tripeptide) as a ready-to-use solution, 50 mg in a 2 mL cartridge (25 mg/mL). No reconstitution: the dial sets a fixed volume per click. The substance is independently tested by HPLC and the Certificate of Analysis is published on this page. For laboratory research use only.
- Purity tested
- Endotoxin tested
- Heavy metals tested
GLP-3 (Retatrutide) Pen 10 mg: pre-filled pen with retatrutide (triple GIP/GLP-1/glucagon receptor agonist) as a ready-to-use solution, 10 mg in a 2 mL cartridge (5 mg/mL). No reconstitution: the dial sets a fixed volume per click. The substance is independently tested by HPLC and the Certificate of Analysis is published on this page. For laboratory research use only.
- Purity tested
- Endotoxin tested
- Heavy metals tested
GLP-3 (Retatrutide) Pen 20 mg Dual-Chamber: dual-chamber pen with 20 mg of lyophilised retatrutide (triple GIP/GLP-1/glucagon receptor agonist) and 1 mL of water in separate chambers of one cartridge. Activation mixes them to 20 mg/mL, so the peptide ships and stores as a dry powder. Certificate of Analysis coming soon. For laboratory research use only.
NAD+ Pen 500 mg: pre-filled pen with NAD+ (nicotinamide adenine dinucleotide) as a ready-to-use solution, 500 mg in a 2 mL cartridge (250 mg/mL). No reconstitution: the dial sets a fixed volume per click. The substance is independently tested by HPLC and the Certificate of Analysis is published on this page. For laboratory research use only.
- Purity tested
- Endotoxin tested
TB-500 Pen 5 mg: pre-filled pen with TB-500 (synthetic peptide derived from thymosin beta-4) as a ready-to-use solution, 5 mg in a 2 mL cartridge (2.5 mg/mL). No reconstitution: the dial sets a fixed volume per click. The substance is independently tested by HPLC and the Certificate of Analysis is published on this page. For laboratory research use only.
- Purity tested
- Endotoxin tested
- Heavy metals tested
Tirzepatide Pen 10 mg: pre-filled pen with tirzepatide (dual GIP/GLP-1 receptor agonist) as a ready-to-use solution, 10 mg in a 2 mL cartridge (5 mg/mL). No reconstitution: the dial sets a fixed volume per click. The substance is independently tested by HPLC and the Certificate of Analysis is published on this page. For laboratory research use only.
- Purity tested
- Endotoxin tested
- Heavy metals tested
